CancerDrs Find care

Breast Cancer clinical trials in New Mexico

10 actively recruiting breast cancer trials at 5 sites across New Mexico.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in New Mexico:
  • University of New Mexico Cancer Center — Albuquerque, New Mexico
  • Presbyterian Kaseman Hospital — Albuquerque, New Mexico
  • Presbyterian Rust Medical Center/Jorgensen Cancer Center — Rio Rancho, New Mexico
Phase 3 Recruiting Industry

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…

Sponsor: AstraZeneca
NCT ID: NCT05952557
Sites in New Mexico:
  • Research Site — Albuquerque, New Mexico
  • Research Site — Farmington, New Mexico
Phase 3 Recruiting Academic/Other

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to der…

Sponsor: American Society of Clinical Oncology
NCT ID: NCT06377852
Sites in New Mexico:
  • Lovelace Medical Center - Saint Joseph Square — Albuquerque, New Mexico
  • Lovelace Women's Hospital — Albuquerque, New Mexico
  • Presbyterian Kaseman Hospital — Albuquerque, New Mexico
  • The University of New Mexico Comprehensive Cancer Center — Albuquerque, New Mexico
  • Memorial Medical Center — Las Cruces, New Mexico
Phase 3 Recruiting Industry

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBC…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05827081
Sites in New Mexico:
  • Presbyterian Medical Group — Albuquerque, New Mexico
Phase 3 Recruiting Industry

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…

Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in New Mexico:
  • Research Site — Albuquerque, New Mexico
Phase 3 Recruiting Industry

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in New Mexico:
  • Clinical Trial Site — Santa Fe, New Mexico
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in New Mexico:
  • University of New Mexico Cancer Center — Albuquerque, New Mexico
Phase 2 Recruiting Industry

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

The purpose of this study is to evaluate the safety and efficacy of the three-drug combination of tucatinib, trastuzumab, and eribulin in patients with de novo and recurrent unresectable metastatic HER-2/neu positive breast cancer as asses…

Sponsor: Criterium, Inc.
NCT ID: NCT05458674
Sites in New Mexico:
  • New Mexico Cancer Care Alliance — Albuquerque, New Mexico
NA Recruiting Network

Mobile Health for Adherence in Breast Cancer Patients

This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to e…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT06112613
Sites in New Mexico:
  • University of New Mexico Cancer Center — Albuquerque, New Mexico
NA Recruiting Academic/Other

The Effect of Hand Exercises on Upper Limb Volume, Quality of Life, and Hand Function in Breast Cancer Survivors

The purpose of this study is to determine whether the addition of simple hand mobility and grip strengthening exercises to the usual care for upper extremity lymphedema will reduce limb volume and improve the quality of life, hand dexterit…

Sponsor: Texas Woman's University
NCT ID: NCT05983380
Sites in New Mexico:
  • Presbyterian Healthplex — Albuquerque, New Mexico
  • Presbyterian Southern Outpatient Rehab — Rio Rancho, New Mexico
  • Presbyterian Santa Fe Medical Center — Santa Fe, New Mexico

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20